Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis

https://doi.org/10.1038/s41467-021-27607-8 17th December 2021

Article highlights & insights

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with a complex microenvironment. Dichotomous tumour-promoting and -restrictive roles have been ascribed to the tumour microenvironment, however the effects of individual stromal subsets remain incompletely characterised. Here, we describe how heterocellular Oncostatin M (OSM) – Oncostatin M Receptor (OSMR) signalling reprograms fibroblasts, regulates tumour growth and metastasis. Macrophage-secreted OSM stimulates inflammatory gene expression in cancer-associated fibroblasts (CAFs), which in turn induce a pro-tumourigenic environment and engage tumour cell survival and migratory signalling pathways. Tumour cells implanted in Osm-deficient (Osm−/−) mice display an epithelial-dominated morphology, reduced tumour growth and do not metastasise. Moreover, the tumour microenvironment of Osm−/− animals exhibit increased abundance of α smooth muscle actin positive myofibroblasts and a shift in myeloid and T cell phenotypes, consistent with a more immunogenic environment. Taken together, these data demonstrate how OSM-OSMR signalling coordinates heterocellular interactions to drive a pro-tumourigenic environment in PDA.

Group leader

Labs & Facilities

Research topics & keywords

Grants

This work was supported by Cancer Research UK Institute Awards A19258, Experimental Medicine Programme Award (A25236) and European Research Council Consolidator Award (ERC-2017-COG 772577).

Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with a complex microenvironment. Here, we describe how heterocellular Oncostatin M (OSM) – Oncostatin M Receptor (OSMR) signalling reprograms fibroblasts, regulates tumour growth and metastasis.

Pancreatic ductal adenocarcinoma